Side Effects by Peptide: What Studies Report — A Literature Index

Peptides are often discussed as a single category, but the published safety record behind them is not uniform. Some peptides have been studied in multi-thousand-participant randomised trials with pre-specified adverse-event capture; others appear mainly in preclinical work, laboratory characterisation, or informal online discussion with no controlled human safety dataset behind them. This page indexes what the verified literature cited below actually reported, compound by compound, and states plainly where that literature is silent. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or medication.

How This Index Reads the Evidence

Adverse-event data are only as good as the design that captured them. A randomised, double-blind, placebo-controlled trial with a pre-registered safety endpoint produces a rate that can be compared against a control arm. A retrospective cohort study produces an association drawn from records. A forum thread or a testimonial produces neither. When a section below says the literature indexed here does not describe a compound's adverse-event profile, that is a statement about the evidence base, not an implied claim that a compound is either safe or unsafe.

Three broad tiers appear across the peptides people ask about most:

• Approved incretin-receptor agonists — semaglutide and tirzepatide — where phase 3 trials, meta-analyses and real-world cohorts have reported dose ranges and adverse-event categories.
• Investigational incretin-family agents — including triple GLP-1/GIP/glucagon receptor agonists such as retatrutide — where class-level reviews exist but compound-specific trial data are not part of the verified set behind this page.
• Research-use and non-trial peptides — GHK-Cu, BPC-157, sermorelin — where the papers indexed here contain no controlled human safety comparisons at all.

Incretin-Receptor Peptides (Semaglutide, Tirzepatide): What Studies Report

This is the only peptide family in the index with a dense, replicated adverse-event record. In SURPASS-1, researchers randomised participants with type 2 diabetes to tirzepatide 5 mg, 10 mg or 15 mg once weekly or placebo in a double-blind phase 3 trial and reported efficacy and safety outcomes for each dose group (PMID 34186022). In a head-to-head trial, tirzepatide 5 mg, 10 mg or 15 mg once weekly was compared with semaglutide 1 mg once weekly in patients with type 2 diabetes, and the study reported gastrointestinal events — nausea, diarrhoea and vomiting — as the most common adverse events across arms (PMID 34170647).

The same gastrointestinal signal recurs in obesity populations. A systematic review and meta-analysis examined the efficacy and safety of semaglutide for weight loss in obesity without diabetes and reported gastrointestinal adverse events among the pooled safety outcomes (PMID 36578889). A randomised comparison of tirzepatide with semaglutide for the treatment of obesity likewise reported gastrointestinal adverse events as the predominant category in both treatment groups (PMID 40353578). A separate clinical cohort study compared semaglutide and tirzepatide for weight loss in adults with overweight or obesity and reported gastrointestinal adverse event rates alongside weight outcomes (PMID 38976257).

Cardiovascular and Longer-Horizon Safety Questions

Longer-term safety in this class has been approached through dedicated outcome trials and real-world analyses. A review of GLP-1 receptor analogues assessed both efficacy and cardiovascular safety across the class (PMID 33292155). SURPASS-CVOT was designed to compare tirzepatide with dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease, and the published paper described the trial design and baseline characteristics rather than outcomes (PMID 37758044). The STEER analysis examined semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in real-world practice (PMID 41491349), and a large cohort study reported clinical outcomes for tirzepatide compared with GLP-1 receptor agonists in individuals with type 2 diabetes (PMID 39133485). A mechanistic and clinical overview positioned tirzepatide as a dual GIP/GLP-1 receptor co-agonist and summarised its glycaemic and body-weight effects in type 2 diabetes (PMID 36050763).

Retatrutide ("Reta"): What Studies Report

Retatrutide is discussed as an investigational agonist acting at the GLP-1, GIP and glucagon (GCGR) receptors. The verified papers behind this page do not include a retatrutide-specific randomised trial, so no retatrutide adverse-event rate, dose range or duration can be reported here. What the indexed literature does provide is class context: a review of GLP-1, GIP/GLP-1 and GCGR/GLP-1 receptor agonists examined this family of agents as therapeutic candidates in metabolic dysfunction-associated steatohepatitis (PMID 39735270). Triple agonists sit inside that reviewed class, but class membership is not evidence of an individual compound's tolerability profile.

Benefits Framing and Why It Is Separated From Safety

Questions that pair "benefits and side effects" assume both come from the same dataset. For the approved incretin agents they often do: the same trial that reported weight and glycaemic outcomes also reported adverse events (PMID 34186022). For an investigational triple agonist, the verified set here contains neither a benefit estimate nor an adverse-event table, so both halves of the question are unanswered by this evidence base.

Sex-Specific and Long-Term Questions

None of the indexed papers are framed as sex-stratified adverse-event analyses, so no separate profile for women or for men can be drawn from them. On duration, the longest-horizon designs in this index belong to the approved agents: a cardiovascular outcome trial design in type 2 diabetes with atherosclerotic disease (PMID 37758044) and a real-world cardiovascular outcome analysis in overweight and obesity (PMID 41491349). Long-term retatrutide safety is not characterised in the literature cited here.

GHK-Cu: What Studies Report

GHK-Cu is a copper-binding tripeptide widely discussed in cosmetic and research contexts. The verified literature set underlying this page contains no controlled human trial of GHK-Cu, and therefore no adverse-event frequency, no concentration, and no exposure duration can be stated here. Readers encountering claims about GHK-Cu tolerability should note the distinction between topical cosmetic ingredient reviews, in-vitro characterisation, and randomised clinical safety data — these are different evidence types that are frequently conflated in summaries that pair "benefits and side effects" in a single sentence.

BPC-157: What Studies Report

BPC-157 is a synthetic peptide sequence that appears chiefly in preclinical and animal-model literature. No controlled human safety trial of BPC-157 is present in the verified papers indexed on this page, so no human adverse-event profile is summarised here. Where a compound's record consists of animal experiments, the translational gap is the central caveat: species, route of administration, exposure duration and endpoint definitions frequently differ from anything measurable in a human trial, and animal tolerability does not establish a human adverse-event rate.

Sermorelin: What Studies Report

Sermorelin corresponds to a fragment of growth hormone-releasing hormone and is discussed in both clinical and non-clinical settings. The verified papers behind this page contain no sermorelin trial, so no adverse-event rate, dose or duration is reported here for any population, including the separate questions people raise about men and about women.

On Forum and Anecdote-Derived Summaries

Discussion-board threads are frequently the most visible source of sermorelin adverse-event descriptions. Such accounts lack denominators, blinding, standardised adverse-event coding and independent verification of what was administered; identical symptoms may be attributed to a peptide, to a co-administered substance, or to unrelated causes. That structural difference is why this index does not convert anecdote into reported rates, and why the only quantified adverse-event categories above come from randomised trials and cohort analyses.

Evidence Availability at a Glance

Context That Changes How Adverse Events Are Interpreted

Adverse-event reporting is also shaped by the clinical setting in which a compound is studied. Metabolic guidelines illustrate this: the EASL-EASD-EASO clinical practice guidelines addressed the management of metabolic dysfunction-associated steatotic liver disease, including the role of weight-directed interventions within a monitored care pathway (PMID 38851997). In that kind of framework, tolerability is assessed alongside baseline disease, comorbidity and laboratory monitoring, none of which exist around informal use. The same compound can therefore generate very different adverse-event pictures depending on who was studied and how closely they were followed.

Regulatory status is a separate axis again. Some peptides in this index are components of approved prescription products with formal labelling and post-marketing surveillance; others are distributed only as research-use-only materials with no such infrastructure, meaning identity, purity and concentration are not independently established and any adverse event cannot be attributed to a verified substance.

What the Literature Does Not Establish

1. That absence of published adverse events implies absence of risk — unstudied is not the same as tolerable.
2. That class-level findings for GLP-1 or GIP/GLP-1 agents transfer to an investigational triple agonist without compound-specific trials.
3. That animal-model tolerability predicts human adverse-event rates.
4. That anecdotal symptom reports can substitute for trial-coded adverse-event data.

Readers comparing peptides are, in practice, comparing evidence bases of very different maturity. The honest summary is that quantified adverse-event reporting in this index exists for the incretin-receptor agonists and does not exist for GHK-Cu, BPC-157, sermorelin or retatrutide.

References

• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Lancet, 2021)
• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (New England Journal of Medicine, 2021)
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
• Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction (Cardiovascular Diabetology, 2022)
• Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (JAMA Internal Medicine, 2024)
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (New England Journal of Medicine, 2025)
• Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes (JAMA Network Open, 2024)
• Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER) (Diabetes, Obesity & Metabolism, 2026)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues (Current Drug Safety, 2021)
• GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis (World Journal of Gastroenterology, 2024)
• EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) (Journal of Hepatology, 2024)